Financials data is unavailable for this security.
View more
Year on year Oncodesign Precision Medicine Opm SA 's revenues fell -86.57% from 7.98m to 1.07m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 231.18k to a larger loss of 8.09m.
Gross margin | 130.48% |
---|---|
Net profit margin | -754.61% |
Operating margin | -927.02% |
Return on assets | -46.23% |
---|---|
Return on equity | -104.58% |
Return on investment | -63.87% |
More ▼
Cash flow in EURView more
SmartText is unavailable
Cash flow per share | -0.4711 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 0.2219 |
---|---|
Tangible book value per share | 0.1529 |
More ▼
Balance sheet in EURView more
Current ratio | 2.53 |
---|---|
Quick ratio | -- |
Total debt/total equity | 2.39 |
---|---|
Total debt/total capital | 0.7052 |
More ▼